Venture capital fund · 1 deal

Healthcare Ventures

Sydney, NSW

Disclosed deals

Every published round Healthcare Ventures took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.

Company	Stage	Announced	Amount	Role	Alongside	Sources
Vaxxas	Series A	4 Aug 2011	$15m	Participant	OneVentures Brandon Capital Medical Research Commercialisation Fund (MRCF)	Brandon BioCatalyst (Tue 18 Feb 2025), Brandon Capital (Tue 18 Feb 2025), Brandon BioCatalyst (Tue 14 Jan 2025), Brandon BioCatalyst (Sun 26 Nov 2023), Brandon Capital (Tue 6 Jun 2023), Brandon Capital (Tue 6 Jun 2023), Brandon BioCatalyst portfolio (Fri 10 Feb 2023), Brandon Capital portfolio (Thu 19 Jan 2023), Brandon BioCatalyst portfolio (Tue 6 Dec 2022), Brandon Capital portfolio (Wed 9 Nov 2022), labonline.com.au (Tue 10 Feb 2015), SmartCompany, labonline.com.au (Tue 2 Aug 2011), Brandon Capital portfolio

Portfolio

Companies Healthcare Ventures has backed in a published round, and companies whose existing shares it bought off another holder.

Company	What it does	First invested	Rounds	Led
Vaxxas		4 Aug 2011, Series A	1	0

Funds

Fund closes reported for Healthcare Ventures, as distinct from the investments it has made.

Fund	Announced	Committed	Target	Close	Sources
No fund closes recorded for Healthcare Ventures yet.

Portfolio companies acquired

Companies Healthcare Ventures has backed that another company then bought. An exit for the holding, not a deal Healthcare Ventures did.

Company	Bought by	Kind	Announced	Price
No portfolio company of Healthcare Ventures is recorded as having been acquired.

Something wrong? Tell us

Healthcare Ventures

Disclosed deals

Portfolio

Funds

Portfolio companies acquired

People

Coverage

Vaxxas Completes Enrollment for Largest Clinical Trial of High-Density Microarray Patch (HD-MAP) For Vaccine Delivery

Vaxxas Completes Enrollment for Largest Clinical Trial of High-Density Microarray Patch (HD-MAP) For Vaccine Delivery

Vaxxas Named Stage Winner of United States’ BARDA Prize to Advance Microarray Patches for Vaccination

Vaxxas Named Stage Winner of United States' BARDA Prize to Advance Microarray Patches for Vaccination

Vaxxas Announces and Publishes Successful Phase I Clinical Trial for Measles and Rubella Vaccine Delivered Using its Proprietary High-Density Microarray Skin Patch; Plan for Phase I/II Trial in The Gambia, Africa

Vaxxas Announces Interim Phase I Study Results for First Needle-Free HD-MAP COVID-19 Vaccine

Vaxxas Appoints Dr. Rochelle Chaiken as Chief Medical Officer

Vaxxas Appoints Dr. Rochelle Chaiken as Chief Medical Officer

Vaxxas initiates Phase I study for needle-free seasonal influenza vaccine delivered using High-Density Microarray Patch (HD-MAP)

Coming in from the cold: needle-free patch technology for mRNA vaccines aims to end need for frozen storage and improve access

Vaxxas Raises US$23 million (A$34 million) to Clinically Advance Needle-Free Vaccines, Including a Next-Generation COVID-19 Vaccine Candidate

Vaxxas Announces Initiation of Phase I Clinical Study of First Needle-Free COVID-19 Vaccine Delivered Using High-Density Microarray Patch (HD-MAP)

Vaxxas Announces Initiation of Phase I Clinical Study of First Needle-Free COVID-19 Vaccine Delivered Using High-Density Microarray Patch (HD-MAP)

First Aussies to get needle-free COVID-19 vaccine patch

First Aussies to get needle-free COVID-19 vaccine patch

Vaxxas Licenses HexaPro Spike Glycoprotein from University of Texas at Austin for Use on its Needle-Free Vaccine Patches

Vaxxas Announces US$22 Million (A$30.6 Million) Award from U.S. Government to Advance Vaxxas Needle-Free HD-MAP™ Vaccine Patch Technology for Pandemic Response

Vaxxas Announces US$22 Million (A$30.6 Million) Award from U.S. Government to Advance Vaxxas Needle-Free HD-MAP™ Vaccine Patch Technology for Pandemic Response

$25 million funding round gives Queensland vaccine biotech Vaxxas a boost

Vaxxas gets $15m injection to develop needle-free vaccine